论文部分内容阅读
作者对72例NHL的治疗方法与预后的关系进行临床探讨。本组结外NHL居多占70．8％，Ⅲ、Ⅳ期病人占45．8％。所有病例均经病理证实。其中22例接受扩大野放射治疗（R组）；50例接受放化疗综合治疗（RC）组。全组3、5、10、15和＞18年生存率分别为61．1％、54．0％、43．8％、35．0％和31．3％。其中R组3、5、10、15和18年以上生存率分别为59．1％、53．2％、23．3％、11．1％和（0／5）；RC组分别为61．4％、57．7％、53．2％、41．1％和38．3％。尽管RC组病情较R组严重，但其各年生存率均高于R组，尤以10年以上生存差别显著。初步结果显示放化疗综合治疗NHL是提高远期生存率的有效方法之一。
The authors investigated the relationship between the treatment methods and prognosis of 72 patients with NHL. The majority of extranodal NHL in this group accounted for 70.8%, and patients in stage III and IV accounted for 45.8%. All cases were confirmed by pathology. Twenty-two patients received expanded field radiation therapy (R group); 50 patients received radiotherapy and chemotherapy combined therapy (RC) group. The 3, 5, 10, 15, and >18-year survival rates for the whole group were 61.1%, 54.0%, 43.8%, 35.0%, and 31.3%, respectively. In the R group, the survival rates of 3, 5, 10, 15, and 18 years or more were 59.1%, 53.2%, 23.3%, 11.1%, and (0/5), respectively; the RC group was 61. 4%, 57.7%, 53.2%, 41.1% and 38.3%. Although the RC group was more severe than the R group, its survival rate in each year was higher than that in the R group, especially in the survival of more than 10 years. The preliminary results show that the comprehensive treatment of NHL with radiotherapy and chemotherapy is one of the effective ways to improve long-term survival.